title: [Taxanes in the treatment of breast and ovarian cancers: current indications and results].
abstract: Since the last years, taxanes are among the most active molecules in the treatment of advanced breast and ovarian cancers. Concerning the ovarian cancer, Paclitaxel in association with Cisplatinum is about to become the first line reference protocol. Studies are going on in order to define the association and the optimal way of administration. Concerning breast cancer, Docetaxel seems to provide the most interesting response rates after failures of anthracyclines. In France, randomised studies in adjuvant situation have started with this molecule.
authors.affiliation: Centre des Maladies du Sein, Oncologie Médicale, Hôpital Saint-Louis, Paris.
authors.forename: M
authors.initials: M
authors.lastname: Espié
authors.forename: C
authors.initials: C
authors.lastname: Cuvier
authors.forename: A
authors.initials: A
authors.lastname: Gorins
authors.forename: M
authors.initials: M
authors.lastname: Marty
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D043823:Taxoids; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel
vernacular_title: Les taxanes dans le traitement des cancers du sein et de l'ovaire: indications actuelles et résultats.